Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events?

By B. Als-Nielsen, Wendong Chen, C. Gluud, L. Kjaergard. Journal of the American Medical Association (JAMA), 2003

761 citations recorded by the source corpus.

Subfields: Pharmacology, Public Health, Environmental and Occupational Health, Statistics and Probability

View Paper: https://www.semanticscholar.org/paper/8abd3cd0718b0fb1eb5b3eb382f0140287d5f794

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacology

1. Douglas G. Altman
2. David Moher

In Public Health, Environmental and Occupational Health

1. Douglas G. Altman
2. P. Gøtzsche
3. Sally Hopewell
4. David Moher
5. K. F. Schulz
6. Karel G. M. Moons
7. John P. A. Ioannidis

In Statistics and Probability

1. Douglas G. Altman
2. P. Gøtzsche
3. David Moher
4. Sally Hopewell
5. P. Glasziou
6. I. Chalmers
7. H. Bastian
8. K. F. Schulz

Citations in the corpus

• PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts (2013, background): “Explanation: Studies of the relationship between pharmaceutical company funding and results of clinical trials have shown that sponsored studies are more likely to have outcomes favouring the sponsor [29,30].”
• Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration (2007, neutral): “3) if the trial was funded by for-profit organisations, even after adjustment for the effect size [223].”